Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial

Table 3

The changes in concentrations of cell markers between days 0–5 and 0–14. Median (range).

Marker median, range of healthy reference subjects, 𝑛	APC; baseline; 𝑛=16	Placebo; baseline; 𝑛=15	𝑃-value	APC; change 0–5 d; 𝑛=14	Placebo; change 0–5 d; 𝑛=12	𝑃-value	APC; change 0–14 d; 𝑛=11	Placebo; change 0–14 d; 𝑛=10	𝑃-value
MoHLA-DR, %; 95.0 (42–99),; 𝑛=64	54.0; (13–73)	44.0; (26–75)	0.599	10.0; (−21–30)	1.00; (−50–22)	0.173	13.0; (−18–37)	31.0; (−29–65)	0.152
MoCD11b, RFU; 126 (72–297),; 𝑛=63	284; (118–770)	337; (136–673)	0.953	−91.5; (−290–123)	−76.5; (−348–114)	0.877	−35.0; (−301–445)	−15.0 (−497–150)	0.349
MoCD14, RFU; 206 (74–379),; 𝑛=64	161; (87–306)	186; (96.0–294)	0.626	−28.5; (−115–68)	−21.5; (−142–58)	0.797	−5.00; (−75–19)	−59.5; (−119–60)	0.173
PMNCD11b,; RFU 130 (75–466),; 𝑛=63	324; (172–791)	325; (161–519)	0.861	−50.5; (−426–236)	−66.0; (−219–164)	0.918	−37.0; (−215–242)	−74.0; (−346–89)	0.173
MoCD62L, RFU; 118 (63–279),; 𝑛=64	217; (133–313)	216; (87–343)	0.892	−65.5; (−208–15)	−68.0; (−226–18)	0.979	−95.5; (−212–11)	−109; (−212–8)	0.481
PMNCD62L,; RFU 131 (85–193); 𝑛=64	123; (40–239)	164; (78–227)	0.264	−46.0; (−212–43)	−67.5; (−123–25)	0.898	−76.0; (−165–69)	−80.0; (−165–65)	0.251

Mo: monocyte; PMN: neutrophil; RFU: relative fluorescence units.